<DOC>
	<DOC>NCT01156844</DOC>
	<brief_summary>This study assessed the bronchodilator efficacy of three different regimens of indacaterol in patients with asthma</brief_summary>
	<brief_title>Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients with a diagnosis of asthma and: Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening FEV1 ≥50% and ≤90% of predicted normal at screening An increase of ≥12% and ≥200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling a total dose of albuterol/salbutamol of 360/400 MDI Smoking history of ≥ 10 years Patients with a diagnosis of COPD Patients who have been previously intubated for a severe asthma exacerbation/ attack Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening Patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to screening Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with seasonal allergy whose asthma is likely to deteriorate during the study period Patients with Type I or uncontrolled Type II diabetes mellitus Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Asthma</keyword>
	<keyword>Bronchodilation</keyword>
	<keyword>Beta-agonist</keyword>
</DOC>